Relationship Between Coronary Plaque Vulnerability and Serum n-3/n-6 Polyunsaturated Fatty Acid Ratio-Reference-Cited by-同舟云学术

Relationship Between Coronary Plaque Vulnerability and Serum n-3/n-6 Polyunsaturated Fatty Acid Ratio

Published:2011 Issue:10 Volume:75 Page:2432-2438
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Kashiyama Toshikazu¹,Ueda Yasunori¹,Nemoto Takayoshi¹,Wada Mitsuru¹,Masumura Yuki¹,Matsuo Koshi¹,Nishio Mayu¹,Hirata Akio¹,Asai Mitsutoshi¹,Kashiwase Kazunori¹,Kodama Kazuhisa¹

Affiliation:

1. Cardiovascular Division, Osaka Police Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://www.jstage.jst.go.jp/article/circj/75/10/75_CJ-11-0352/_pdf

Reference24 articles.

1. GUY's HOSPITAL.

2. Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study

3. 3. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: A systematic review. Clin Cardiol 2009; 32: 365-372.

4. 4. Domei T, Ueeda M, Takaya Y, Ohnishi N, Takaishi A, Imai M, et al. The balance of n6/n3 polyunsaturated fatty acid (PUFAs) is important factor of prognosis after acute myocardial infarction. Circulation 2006; 114: II-463.

5. 5. Domei T, Kuramitsu S, Ando K, Soga Y, Arita T, Shirai S, et al. The relationship between the ratio of serum eicosapentaenoic acid (EPA) to arachidonic acid (AA) with major cardiac events in patients undergoing elective percutaneous coronary intervention. Circulation 2009; 120: S426.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in therapeutic applications of fish oil: A review;Measurement: Food;2024-03

2. Erythrocyte membrane fluidity: A novel biomarker of residual cardiovascular risk in type 2 diabetes;European Journal of Clinical Investigation;2023-11-06

3. N-3 Polyunsaturated Fatty Acids and Their Role on Cardiovascular System;Fatty Acids - From Biosynthesis to Human Health;2023-05-31

4. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid;Pharmacology & Therapeutics;2022-09

5. Pharmacokinetics of Icosapent Ethyl: An Open‐Label, Multiple Oral Dose, Parallel Design Study in Healthy Chinese Subjects;Clinical Pharmacology in Drug Development;2022-07-03